Research Article
Thromboembolic Events Secondary to Endoscopic Cyanoacrylate Injection: Can We Foresee Any Red Flags?
Table 2
Postoperative events including subsequent severe adverse event (SAE), patient outcome, and probable cause.
| Patient | Postoperative drug use | Adverse event | Treatment | Hospital stay | Outcome | Probable cause |
| (1) | None | Acute pulmonary embolism | BCLS | 1 day | Death | Large spontaneous gastrorenal and splenorenal shunt |
| (2) | Carbazochrome 80 mg Vitamin K1 10 mg Somatostatin 6 mg | Acute splenic infarction | Dalteparin 5000 IU Antibiotics (meropenem + vancomycin) | 64 days | Survival | Regurgitation of tissue adhesive through the portovenous system or probable AVM |
| (3) | Carbazochrome 80 mg Somatostatin 3 mg Hemocoagulase 2 U | Acute cerebral infarction | Dalteparin 5000 IU Edaravone Mannitol Dexamethasone | 13 days | Survival | Spontaneous portorenal shunt |
| (4) | Hemocoagulase 1 IU Somatostatin 6 mg | Acute superior mesenteric infarction | LMWH 4000 IU Simethicone p.o. | 9 days | Death | Regurgitation of tissue adhesive through the portovenous system or probable AVM |
| (5) | Hemocoagulase 1 IU Somatostatin 6 mg | Acute cerebral infarction | LMWH 4000 IU Citicoline GM-1 Dexamethasone | 42 days | Survival | Spontaneous portoazygous shunt |
|
|